Abstract
11537 Background: Current management of BC pts with HER2 overexpression includes chemotherapy and trastuzumab treatment. In order to assess the potential individual benefit of this treatment we analyzed outcome data and prognostic factors in a prospectively characterized cohort of HER2 positive BC pts treated before the trastuzumab era. Methods: Medical records from 103 HER2 positive BC pts treated between 1996 and 2005 according to our standard institutional protocols without adjuvant trastuzumab were analyzed. Clinicopathologic variables such as age, menopausal status, clinical stage, pathologic tumor size (pTS), histologic grade (HG), ER and PR status, lymphovascular invasion (LVI) and axillary lymph node (ALN) status were extracted from the institutional database that has been prospectively collected since 1996. Variables with a 0.15 significance level in univariate analysis were entered in a multivariate Cox model. A backward stepwise procedure discriminated non-influential variables at 0.05 level. R...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call